Category Archives: Regenerative Medicine

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the World Stem Cell Summit 2012 in West Palm Beach, Florida on Tuesday, December 4, 2012. Dr. West will be presenting in the session on Developing Combination Products: Cells, Genes, and Devices at 1:30 pm EST which will include an update on product development, including Renevia, PanC-Dx, and OpRegen. The presentation will be made available on BioTime's website at http://www.biotimeinc.com.

World Stem Cell Summit 2012 will be the 8th annual event produced by the Genetics Policy Institute (GPI), a non-profit organization. Planned by and for the stem cell and regenerative medicine community, the goal of the Summit is to accelerate the discovery and development of lifesaving cures and therapies. This year, panels will address advancing treatments for specific diseases and conditions including: cancer, diabetes, HIV/AIDS, cardiovascular disease, spinal cord injury, paralysis, multiple sclerosis, ALS, Parkinson's, eye diseases and others.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Read more from the original source:
BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012

Stem cell banks could serve as a valuable resource for emerging treatments in the field of regenerative medicine, though challenges remain to making them a reality, according to a panel of international experts who gathered at UCSF for a stem cell conference last month.

Funding for the development of stem cell lines for research has long been subject to debate, especially before President Barack Obama lifted a Bush-era ban on federal funding in 2009, but now scientists are discussing how to best meet the anticipated need for stem cells for medicine as well as research.

Stem cell treatments developed from adult cells rather than from embryonic tissue are expected to enter clinical trials for macular degeneration in Japan next year, and early successes in such trials aimed at replacing damaged tissues would be expected to drive demand for such stem cells upward. Worldwide, stem cell scientists in academia, government and the private sector are gauging strategies for moving forward with stem cell banks to meet expected demand.

So far, countries have been taking different paths toward acquiring these resources, panelists said at an Oct. 25 discussion at the International Society for Stem Cell Research conference held at the UCSF Mission Bay campus.

Shinya Yamanaka, MD, PhD

Panelists for the discussion, titled Challenges and Opportunities in Cellular Reprogramming, included Shinya Yamanaka, MD, PhD, a UCSF professor of anatomy senior investigator with the UCSF-affiliated Gladstone Institutes who won the 2012 Nobel Prize for Physiology or Medicine for discoveries that are the groundwork for many of todays regenerative medicine strategies.

Yamanaka, who is also director of the Center for iPS Cell Research and Application at Kyoto University, has advocated stem cell banking for medicine in his native Japan, where the government recently made a commitment to begin stem cell banking.

Yamanaka pioneered the use of induced pluripotent stem (iPS) cells, which are created when individuals provide skin cells or other easily obtained cells that scientists then reprogram in the lab to become virtually any cell type. One of primary advantages to iPS cells is that their use overcomes ethical objections to the use of embryonic stem cells, which are developed from leftover embryos obtained from in vitro fertilization clinics.

Because iPS cells can be created from the cells of individuals afflicted with specific diseases, they can be used to develop new disease models to learn more about how diseases arise and how they might be treated. But in addition, panelists emphasized, iPS cells can be reprogrammed to become long-lived stem cells specialized for particular organs and tissues and play a role in treatments now being developed for regenerative medicine.

Our effort in Japan is to establish iPS stocks for regenerative medicine, Yamanaka said.

More:
Stem Cell Banks Envisioned for Regenerative Medicine

SCMOM 2012_UC Davis - Wheelock
UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university #39;s hub for stem cell science. It includes Northern California #39;s largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university #39;s Clinical and Translational Science Center, and focus on turning stem cells into cures. http://www.ucdmc.ucdavis.edu/stemcellresearch Presenter: Vicki L. Wheelock, MD, Clinical Professor, Neurology, Director, HDSA Center of Excellence, Principle Investigator, CIRM Grant DR2A-05415, UC Davis Health SystemFrom:AllianceRegenMedViews:1 0ratingsTime:12:18More inScience Technology

Go here to read the rest:
SCMOM 2012_UC Davis - Wheelock - Video

SCMOM 2012_Owl Biomedical
Owl biomedical is an emerging company commercializing an innovative high-speed, disposable cartridge-based cell sorting platform called the Nanosorter®. The Nanosorter® enables rapid processing of large numbers of cells safely without aerosols and in a simple, readily deployable and easy to use system. The Nanosorter® platform uniquely combines the world #39;s fastest microvalve (fabricated within a microchip) and the well-proven principles of fluorescence-activated sorting of cells. Cells purified using the Nanosorter® can be employed for a wide variety of commercial applications, including: adoptive immunotherapy for treatment of cancer, stem cell therapies for regenerative medicine (eg stroke, limb ischemia, wound healing), cell-based cancer diagnostics, and a wide variety of cell-based applied research applications. Owl biomedical was founded in 2011 and is based in Santa Barbara, California. http://www.owlbiomedical.com Presenter: Jim Linton, Ph.D., MBA, President and Chief Business Officer, Owl BiomedicalFrom:AllianceRegenMedViews:7 1ratingsTime:15:31More inScience Technology

See the article here:
SCMOM 2012_Owl Biomedical - Video

SCMOM 2012_Cedars-Sinai Regenerative Medicine Institute
The Cedars-Sinai Regenerative Medicine Institute (RMI) brings together research faculty and clinicians to provide a true "bench to bedside" organization. We have five major programs of research: (i) Brain, (ii) Eye, (iii) Pancreas and Liver, (iv) Blood and (v) Skeletal. Working within each of these programs benefits from our core facilities with a focus on generating induced pluripotent stem cells from adult human skin samples and optimizing differentiation into various tissues of the human body of interest to the six programs. The pluripotent cells are used to both increase our understanding of human diseases through modeling, and provide a foundation for pre-clinical studies aimed at establishing and validating cellular therapeutic approaches to human illness. http://www.cedars-sinai.edu/Research-and-Education/Institutes/Regenerative-Medicine-Institute Presenter: Clive Svendsen, Ph.D., Director, Cedars-Sinai Regenerative Medicine InstituteFrom:AllianceRegenMedViews:1 0ratingsTime:13:27More inScience Technology

Visit link:
SCMOM 2012_Cedars-Sinai Regenerative Medicine Institute - Video

SCMOM 2012_Regenerative Patch Technologies
Regenerative Patch Technologies was formed to advance development of a composite RPE cell-membrane technology currently supported by a disease team award to the University of Southern California, the University of California, Santa Barbara, and the California Institute of Technology from the California Institute of Regenerative Medicine. The technology utilizes polarized RPE cells derived from human embryonic stem cells together with an ultrathin biocompatible parylene membrane as a replacement for the defective Bruch #39;s membrane RPE cell complex often observed in patients with the atrophic form of age related macular degeneration. The project is progressing through preclinical studies to enable IND filing in 2014. http://www.regenerativepatch.com Presenter: Jane Lebkowski, President and CSO, Regenerative Patch TechnologiesFrom:AllianceRegenMedViews:11 1ratingsTime:15:22More inScience Technology

The rest is here:
SCMOM 2012_Regenerative Patch Technologies - Video

The Cure: A Documentary on Regenerative Medicine (Part 1)
Filmmaker David Alvarado tells the remarkable, behind-the-scenes story on the founding of the Silicon Valley Institute of Regenerative Medicine. Through a public/private partnership with Santa Clara Valley Medical Center, Stanford University, the County of Santa Clara, the Palo Alto VA and others, the Institute hopes to facilitate major breakthroughs in the treatment of spinal cord and other injuries using stem cells.From:VMCFoundationViews:2 0ratingsTime:07:07More inScience Technology

Read more from the original source:
The Cure: A Documentary on Regenerative Medicine (Part 1) - Video

EATONTOWN, N.J., Nov. 27, 2012 (GLOBE NEWSWIRE) -- American CryoStem Corporation (CRYO), a leading biotech company in the Regenerative Medicine industry, announced today that it has entered into an agreement with XeoStem LLC of Coral Gables, FL in which CRYO will provide its proprietary adipose tissue processing and storage services. The initial agreement allows XeoStem to market CRYO's adipose tissue platform, stem cell processing services, patented products and banking technology for tissue grafting and "bio-insurance" purposes to their patients and groups of physicians.

"American CryoStem's proprietary platform is designed to service individual physicians and large physician networks like XeoStem offering Regenerative Medicine services. We continually strive to work with leading medical professionals and organizations developing cellular therapies and related services," stated John Arnone, CEO of American CryoStem. "This is one of many strategic opportunities to leverage our technology and augment our direct to consumer and physician marketing efforts."

Additionally XeoStem operates a dedicated management company, XeoStem MD, for recruiting and training physicians on the latest tissue transfer techniques, banking and adult stem cell applications. Under the agreement, all XeoStem branded services will include the tagline "Processed by American CryoStem."

"XeoStem incorporates the latest web technology, print, social media marketing techniques and educational seminars to facilitate access and adoption of our services," stated Dr. Abuzeni, CEO of XeoStem. "We are focused on the overall patient and physician experience, and have developed web-applications specifically designed to inform our network concerning the latest Regenerative Medicine advancements."

About XeoStem: XeoStem, LLC was founded by Dr. Patrick Abuzeni to deliver adipose tissue and stem cell services and practical knowledge to patients and affiliated physicians. XeoStem believes that stem cells have the potential of transforming the future of medicine in cosmetic, orthopedic and disease management applications. XeoStem has partnered with American CryoStem, a leader in processing and biological banking of Adipose (fat) tissue and Adult Adipose Derived Stem Cells to provide the highest quality, reliable and economic adipose tissue and stem cell processing and storage.

About American CryoStem: American CryoStem Corporation (CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and Regenerative Medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.

Excerpt from:
American CryoStem Corporation and XeoStem LLC Complete Adipose Stem Cell Processing and Tissue Banking Agreement

EATONTOWN, N.J., Nov. 27, 2012 (GLOBE NEWSWIRE) -- American CryoStem Corporation (CRYO), a leading biotech company in the Regenerative Medicine industry, announced today that it has entered into an agreement with XeoStem LLC of Coral Gables, FL in which CRYO will provide its proprietary adipose tissue processing and storage services. The initial agreement allows XeoStem to market CRYO's adipose tissue platform, stem cell processing services, patented products and banking technology for tissue grafting and "bio-insurance" purposes to their patients and groups of physicians.

"American CryoStem's proprietary platform is designed to service individual physicians and large physician networks like XeoStem offering Regenerative Medicine services. We continually strive to work with leading medical professionals and organizations developing cellular therapies and related services," stated John Arnone, CEO of American CryoStem. "This is one of many strategic opportunities to leverage our technology and augment our direct to consumer and physician marketing efforts."

Additionally XeoStem operates a dedicated management company, XeoStem MD, for recruiting and training physicians on the latest tissue transfer techniques, banking and adult stem cell applications. Under the agreement, all XeoStem branded services will include the tagline "Processed by American CryoStem."

"XeoStem incorporates the latest web technology, print, social media marketing techniques and educational seminars to facilitate access and adoption of our services," stated Dr. Abuzeni, CEO of XeoStem. "We are focused on the overall patient and physician experience, and have developed web-applications specifically designed to inform our network concerning the latest Regenerative Medicine advancements."

About XeoStem: XeoStem, LLC was founded by Dr. Patrick Abuzeni to deliver adipose tissue and stem cell services and practical knowledge to patients and affiliated physicians. XeoStem believes that stem cells have the potential of transforming the future of medicine in cosmetic, orthopedic and disease management applications. XeoStem has partnered with American CryoStem, a leader in processing and biological banking of Adipose (fat) tissue and Adult Adipose Derived Stem Cells to provide the highest quality, reliable and economic adipose tissue and stem cell processing and storage.

About American CryoStem: American CryoStem Corporation (CRYO) is a leading biotech company focused on marketing its clinical processing services and patented products for adipose (fat) tissue and adipose derived adult stem cells. Our clinical tissue processing, patented cell culture media products and tissue storage platform supports cosmetic and Regenerative Medicine applications being developed globally. The Company provides high quality, clinically processed viable cells, while at the same time developing cutting edge applications, therapies, patented laboratory products and services for consumer and commercial applications.

Excerpt from:
American CryoStem Corporation and XeoStem LLC Complete Adipose Stem Cell Processing and Tissue Banking Agreement

cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life
http://www.cordbloodrecommendation.com A large number of people die waiting for a transplant due to this reason. Well, there are still debates on this issue. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. There is also another option given by non-profit cord blood banks, of free programs through which one can store umbilical cord blood stem cell samples. Others choose to donate the blood to a public bank for the public good. Given the progress that stem cell research and regenerative medicine have attained at present, and the promise that they show for the future, stem cell transplants may one day provide a cure for type 1 diabetes, heart disease, and brain injury, among other potentially life threatening and debilitating illnesses and conditions with inadequate treatment options today. One study in particular by Wagner, et al. ""Settling on a name for your newborn is definitely something all parents spend time doing, but one decision that is rarely thought of or overlooked is saving your newborn #39;s cord blood. However, you can choose to make a once-in-a-lifetime decision to collect and store your baby #39;s cord blood stem cells after the birth of your newborn baby. It is able to kill either normal or cancer-producing blood cells of the bone marrow. Your child #39;s umbilical cord blood contains special cells known as stem cells. Thus, it ...From:Alexander santafeViews:0 0ratingsTime:01:31More inScience Technology

Read the original here:
cord blood donation | How Cord Blood Stem Cell Can Bring Hope to People Suffering From Life - Video